ACADIA Total Stockholder Equity vs Short Term Debt Analysis

ACAD Stock

USD 16.29 0.08 0.49%

ACADIA Pharmaceuticals financial indicator trend analysis is way more than just evaluating ACADIA Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ACADIA Pharmaceuticals is a good investment. Please check the relationship between ACADIA Pharmaceuticals Total Stockholder Equity and its Short Term Debt accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.

Total Stockholder Equity vs Short Term Debt

Total Stockholder Equity vs Short Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ACADIA Pharmaceuticals Total Stockholder Equity account and Short Term Debt. At this time, the significance of the direction appears to have weak relationship.

The correlation between ACADIA Pharmaceuticals' Total Stockholder Equity and Short Term Debt is 0.33. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Short Term Debt in the same time period over historical financial statements of ACADIA Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of ACADIA Pharmaceuticals' Total Stockholder Equity and Short Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of ACADIA Pharmaceuticals are associated (or correlated) with its Short Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Short Term Debt has no effect on the direction of Total Stockholder Equity i.e., ACADIA Pharmaceuticals' Total Stockholder Equity and Short Term Debt go up and down completely randomly.

Correlation Coefficient

0.33

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Short Term Debt

Most indicators from ACADIA Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ACADIA Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.At present, ACADIA Pharmaceuticals' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 1.8 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.51.

	2021	2022	2023	2024 (projected)
Cost Of Revenue	19.1M	10.2M	45.7M	25.4M
Depreciation And Amortization	3.3M	2.0M	5.6M	5.8M

Cost Of Revenue Depreciation And Amortization

ACADIA Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Total Stockholder Equity	Net Debt	Other Assets	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Current Deferred Revenue	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Short Term Investments	Other Current Assets	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.69	0.86	-0.77	0.29	0.93	0.66	0.96	0.73	0.76	0.76	0.74	0.39	-0.91	0.75	0.88	0.74	0.92	0.87	0.93	0.8	0.87	0.74	0.99	0.69	0.93
Short Long Term Debt Total	0.69		0.35	-0.3	0.39	0.72	0.98	0.82	0.9	0.83	0.84	0.98	0.05	-0.86	0.83	0.58	0.94	0.6	0.36	0.74	0.26	0.84	0.99	0.6	0.95	0.74
Total Stockholder Equity	0.86	0.35		-0.81	0.24	0.78	0.31	0.75	0.3	0.34	0.34	0.44	0.51	-0.68	0.36	0.79	0.33	0.85	1.0	0.74	0.96	0.53	0.41	0.91	0.33	0.74
Net Debt	-0.77	-0.3	-0.81		-0.45	-0.65	-0.3	-0.64	-0.36	-0.41	-0.4	-0.39	-0.47	0.57	-0.37	-0.95	-0.36	-0.74	-0.82	-0.65	-0.64	-0.55	-0.38	-0.81	-0.24	-0.65
Other Assets	0.29	0.39	0.24	-0.45		0.1	0.41	0.25	0.31	0.19	0.2	0.47	-0.13	-0.27	0.18	0.52	0.29	0.4	0.25	0.08	0.04	0.31	0.44	0.27	0.21	0.08
Common Stock Shares Outstanding	0.93	0.72	0.78	-0.65	0.1		0.67	0.96	0.7	0.74	0.75	0.75	0.44	-0.93	0.76	0.78	0.74	0.82	0.79	0.99	0.74	0.83	0.75	0.92	0.73	0.99
Non Current Liabilities Total	0.66	0.98	0.31	-0.3	0.41	0.67		0.79	0.9	0.81	0.83	0.98	-0.04	-0.84	0.81	0.58	0.93	0.59	0.32	0.69	0.2	0.83	0.98	0.57	0.91	0.69
Other Stockholder Equity	0.96	0.82	0.75	-0.64	0.25	0.96	0.79		0.82	0.82	0.83	0.84	0.3	-0.99	0.84	0.81	0.84	0.9	0.76	0.96	0.69	0.92	0.85	0.92	0.8	0.96
Total Liab	0.73	0.9	0.3	-0.36	0.31	0.7	0.9	0.82		0.98	0.98	0.87	0.02	-0.85	0.94	0.61	0.99	0.61	0.33	0.75	0.22	0.94	0.91	0.63	0.9	0.75
Other Current Liab	0.76	0.83	0.34	-0.41	0.19	0.74	0.81	0.82	0.98		1.0	0.79	0.1	-0.85	0.95	0.63	0.96	0.61	0.36	0.81	0.27	0.95	0.84	0.67	0.85	0.81
Total Current Liabilities	0.76	0.84	0.34	-0.4	0.2	0.75	0.83	0.83	0.98	1.0		0.81	0.09	-0.85	0.96	0.63	0.97	0.61	0.36	0.81	0.28	0.95	0.86	0.67	0.87	0.81
Property Plant And Equipment Net	0.74	0.98	0.44	-0.39	0.47	0.75	0.98	0.84	0.87	0.79	0.81		0.06	-0.88	0.8	0.65	0.92	0.68	0.45	0.75	0.33	0.84	1.0	0.66	0.9	0.75
Current Deferred Revenue	0.39	0.05	0.51	-0.47	-0.13	0.44	-0.04	0.3	0.02	0.1	0.09	0.06		-0.24	0.11	0.41	0.05	0.23	0.52	0.4	0.51	0.1	0.05	0.44	0.11	0.4
Retained Earnings	-0.91	-0.86	-0.68	0.57	-0.27	-0.93	-0.84	-0.99	-0.85	-0.85	-0.85	-0.88	-0.24		-0.87	-0.76	-0.87	-0.87	-0.69	-0.93	-0.62	-0.93	-0.89	-0.87	-0.84	-0.93
Accounts Payable	0.75	0.83	0.36	-0.37	0.18	0.76	0.81	0.84	0.94	0.95	0.96	0.8	0.11	-0.87		0.59	0.93	0.61	0.39	0.8	0.32	0.9	0.84	0.67	0.85	0.8
Cash	0.88	0.58	0.79	-0.95	0.52	0.78	0.58	0.81	0.61	0.63	0.63	0.65	0.41	-0.76	0.59		0.61	0.82	0.8	0.79	0.62	0.75	0.65	0.88	0.5	0.79
Non Current Assets Total	0.74	0.94	0.33	-0.36	0.29	0.74	0.93	0.84	0.99	0.96	0.97	0.92	0.05	-0.87	0.93	0.61		0.61	0.35	0.78	0.25	0.94	0.95	0.65	0.93	0.78
Non Currrent Assets Other	0.92	0.6	0.85	-0.74	0.4	0.82	0.59	0.9	0.61	0.61	0.61	0.68	0.23	-0.87	0.61	0.82	0.61		0.86	0.81	0.79	0.81	0.66	0.92	0.55	0.81
Cash And Short Term Investments	0.87	0.36	1.0	-0.82	0.25	0.79	0.32	0.76	0.33	0.36	0.36	0.45	0.52	-0.69	0.39	0.8	0.35	0.86		0.75	0.95	0.55	0.42	0.92	0.35	0.75
Common Stock Total Equity	0.93	0.74	0.74	-0.65	0.08	0.99	0.69	0.96	0.75	0.81	0.81	0.75	0.4	-0.93	0.8	0.79	0.78	0.81	0.75		0.7	0.88	0.76	0.91	0.76	1.0
Short Term Investments	0.8	0.26	0.96	-0.64	0.04	0.74	0.2	0.69	0.22	0.27	0.28	0.33	0.51	-0.62	0.32	0.62	0.25	0.79	0.95	0.7		0.45	0.3	0.86	0.3	0.7
Other Current Assets	0.87	0.84	0.53	-0.55	0.31	0.83	0.83	0.92	0.94	0.95	0.95	0.84	0.1	-0.93	0.9	0.75	0.94	0.81	0.55	0.88	0.45		0.87	0.81	0.83	0.88
Property Plant And Equipment Gross	0.74	0.99	0.41	-0.38	0.44	0.75	0.98	0.85	0.91	0.84	0.86	1.0	0.05	-0.89	0.84	0.65	0.95	0.66	0.42	0.76	0.3	0.87		0.66	0.91	0.76
Total Current Assets	0.99	0.6	0.91	-0.81	0.27	0.92	0.57	0.92	0.63	0.67	0.67	0.66	0.44	-0.87	0.67	0.88	0.65	0.92	0.92	0.91	0.86	0.81	0.66		0.6	0.91
Short Term Debt	0.69	0.95	0.33	-0.24	0.21	0.73	0.91	0.8	0.9	0.85	0.87	0.9	0.11	-0.84	0.85	0.5	0.93	0.55	0.35	0.76	0.3	0.83	0.91	0.6		0.76
Common Stock	0.93	0.74	0.74	-0.65	0.08	0.99	0.69	0.96	0.75	0.81	0.81	0.75	0.4	-0.93	0.8	0.79	0.78	0.81	0.75	1.0	0.7	0.88	0.76	0.91	0.76

Click cells to compare fundamentals

ACADIA Pharmaceuticals Account Relationship Matchups

ACADIA Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	783.2M	782.6M	700.1M	587.8M	749.0M	786.4M
Total Stockholder Equity	699.1M	627.0M	540.9M	400.4M	431.8M	232.8M
Net Debt	(183.3M)	(281.6M)	(91.3M)	(52.8M)	(131.5M)	(124.9M)
Other Assets	5.3M	54.7M	16.0M	11.1M	12.7M	7.9M
Common Stock Shares Outstanding	147.2M	157.3M	160.5M	161.7M	163.8M	172.0M
Liabilities And Stockholders Equity	783.2M	782.6M	700.1M	587.8M	749.0M	786.4M
Non Current Liabilities Total	9.2M	49.6M	63.2M	61.8M	62.9M	66.1M
Other Stockholder Equity	2.4B	2.6B	2.7B	2.8B	2.9B	3.0B
Total Liab	84.0M	155.6M	159.2M	187.4M	317.2M	333.1M
Other Current Liab	64.2M	92.4M	80.9M	103.2M	225.7M	237.0M
Total Current Liabilities	74.8M	106.0M	96.1M	125.6M	254.3M	267.0M
Property Plant And Equipment Net	12.7M	56.4M	66.3M	61.6M	56.5M	59.3M
Retained Earnings	(1.7B)	(2.0B)	(2.2B)	(2.4B)	(2.4B)	(2.3B)
Accounts Payable	7.2M	8.5M	6.9M	12.7M	17.5M	18.4M
Cash	189.7M	326.0M	147.4M	114.8M	188.7M	198.1M
Non Current Assets Total	22.9M	65M	82.3M	79.9M	132.8M	139.5M
Non Currrent Assets Other	7.6M	7.4M	6.6M	5.3M	5.1M	5.4M
Cash And Short Term Investments	697.4M	632.0M	520.7M	416.8M	438.9M	269.3M
Short Term Investments	507.7M	305.9M	373.3M	302.0M	250.2M	185.1M
Other Current Assets	18.6M	25.7M	23.9M	21.4M	39.1M	41.0M
Property Plant And Equipment Gross	12.7M	56.4M	66.3M	61.6M	66.0M	69.3M
Total Current Assets	760.3M	717.6M	617.8M	507.9M	616.1M	646.9M
Accumulated Other Comprehensive Income	297K	36K	(192K)	(975K)	24K	25.2K
Property Plant Equipment	3.2M	9.2M	66.3M	61.6M	70.8M	74.4M
Other Liab	2.9M	5.2M	7.0M	9.1M	10.4M	11.0M
Net Tangible Assets	696.6M	625.9M	540.9M	400.4M	460.5M	403.1M
Retained Earnings Total Equity	(1.5B)	(1.7B)	(2.0B)	(2.2B)	(1.9B)	(1.8B)
Capital Surpluse	1.9B	2.4B	2.6B	2.7B	3.1B	1.6B
Inventory	6.3M	9.7M	7.9M	6.6M	35.8M	37.6M
Intangible Assets	4.1M	2.6M	1.1M	65.5M	75.3M	79.1M
Net Receivables	37.9M	50.3M	65.3M	63.1M	102.4M	107.5M
Non Current Liabilities Other	9.2M	49.6M	7.0M	9.1M	15.1M	12.7M
Net Invested Capital	699.1M	627.0M	540.9M	400.4M	431.8M	401.6M
Net Working Capital	685.4M	611.6M	521.8M	382.3M	361.9M	383.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:

How To Invest In ACADIA

Details

Is ACADIA Stock a good investment?

Details

What is ACADIA Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.

You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

28.347

Earnings Share

0.78

Revenue Per Share

5.622

Quarterly Revenue Growth

0.183

Return On Assets

0.0872

The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ACADIA Total Stockholder Equity vs Short Term Debt Analysis

Total Stockholder Equity vs Short Term Debt

Total Stockholder Equity vs Short Term Debt Correlation Analysis

Correlation Coefficient

Total Stockholder Equity

Short Term Debt

ACADIA Pharmaceuticals fundamental ratios Correlations

ACADIA Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ACADIA Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Liabilities	+ 1.0	Other Current Liab
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Common Stock	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Short Long Term Debt Total

Retained Earnings	- 0.99	Other Stockholder Equity
Cash	- 0.95	Net Debt
Common Stock	- 0.93	Retained Earnings
Other Current Assets	- 0.93	Retained Earnings
Common Stock Total Equity	- 0.93	Retained Earnings
Retained Earnings	- 0.93	Common Stock Shares Outstanding